Fig. 1: Study flow chart of patients and lesions included in the analysis of the primary, secondary and exploratory endpoints of ZEPHIR clinical trial.
n number, BC breast cancer, T-DM1 trastuzumab emtansine, TTF time-to-treatment failure.
Fig. 1: Study flow chart of patients and lesions included in the analysis of the primary, secondary and exploratory endpoints of ZEPHIR clinical trial. | npj Breast Cancer
